Search

Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.

Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

• News
• Retinitis pigmentosa

Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.

• News
• Retinitis pigmentosa

You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.

• News
• Retinitis pigmentosa

In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.

• News

Information for healthcare professionals: Genetic testing and counselling in inherited retinal disease

Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.

• News
• Leber congenital amaurosis (LCA)
• Retinitis pigmentosa

Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.

Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.

• Case study - research
• Written

Retina UK invites applications for funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease. We are particularly keen to receive proposals with demonstrable translational potential.

• News